Gilead Sciences Inc (GILD) Stock Price

GILDStock
$148.77+27.86%52W
Market Cap$184.47B
P/E19.96x
PEG Ratio2.14
Div yield3.98%
Beta0.34

GILD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.17%
Price vs S&P 500 (4W)6.19%
PEG Ratio2.14
VGM Score60.01
P/E Ratio (Annual)19.96x
Indicated Dividend Yield (Annual)3.98%

GILD Earnings Surprise History

Q2 252.01est. 1.96
Q3 252.47est. 2.14
Q4 251.86est. 1.81
Q1 262.03est. 1.91
Q2 26-6.75est. -7.25

GILD Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.08
4.10
4.08
4.05

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
GILDGilead Sciences Inc
CBB$148.77
AMGNAmgen IncCCB$442.24
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32
TECHBio-Techne Corp.DCB$72.33

About Gilead Sciences Inc

Gilead Sciences develops therapies for life-threatening infectious diseases, with a portfolio focused on HIV and hepatitis B and C. The company's hepatitis C franchise, anchored by Sovaldi, remains a standard of care in combination regimens. Gilead is strategically expanding into oncology through recent acquisitions including CAR-T cell therapy Yescarta/Tecartus and solid tumor therapy Trodelvy.